RT Journal Article
SR Electronic
T1 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2087
DO 10.1183/13993003.congress-2016.PA2087
VO 48
IS suppl 60
A1 Monika Zurková
A1 Vítezslav Kolek
A1 Vladimíra Loštáková
A1 Eva Kriegová
A1 Martina Šterclová
A1 Vladimír Bartoš
A1 Martina Doubková
A1 Ilona Binková
A1 Michal Svoboda
A1 Jana Strenková
A1 Martina Placková
A1 Ladislav Lacina
A1 Vladimir Rihak
A1 František Petrík
A1 Pavlína Lisá
A1 Radka Bittenglová
A1 Richard Tyl
A1 Gustav Ondrejka
A1 Hana Suldova
A1 Jaroslav Lnenicka
A1 Jana Pšikalová
A1 Tomáš Snízek
A1 Jirí Homolka
A1 Renata Králova
A1 Jan Kervitzer
A1 Martina Vašáková
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA2087.abstract
AB Aims and objectives: The aim of the study was to compare the annual declineof lung functions during treatment with pirfenidone in comparison to triple-combination and other treatment modalities in Czech patients with IPF.Methods: Currently, the Czech IPF registry consists of 517 patients diagnosed with IPF-UIP. Our retrospective study included 72 patients treated with pirfenidone, 27 with triple-combination and 97 received other treatment modalities. To estimate the annual change of FVC and TLCO, a linear regression model with mixed effects was used. p-value < 0.05 was considered as significant.Results: The comparison of changes in lung function over a 1-year follow-up showed lower decrease in the predicted value (PV) of FVC in pirfenidon group than in triple-combination (-0.093 vs -0.222, p-value=0.026) and trend to lower decrease in comparison to other treatment modalities (-0.093 vs -0.162, p-value=0.082). Also, a 1-year decrease in the PV of a TLCO was smaller in pirfenidon group than in triple-combination (0.221 vs -0.453, p-value=0.096) and other modalities group (-0.221 vs -0.389, p-value=0.082); however the decrease did reach significancy between studied groups.Conclusion: In Czech IPF patients, pirfenidone administration was associated with the lower decrease in lung function (FVC, TLCO) comparing with other treatment modalities. Our observation supports current recommendation of pirferidon for mild and moderate IPF.Supported by IGA_LF_2016_011.